Karyopharm Therapeutics Inc (NAS:KPTI)
$ 1.06 0.05 (4.9%) Market Cap: 123.45 Mil Enterprise Value: 104.37 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 76/100

Karyopharm Therapeutics Inc at Jefferies London Healthcare Conference (Virtual) - On-Demand Transcript

Nov 18, 2021 / 08:00AM GMT
Release Date Price: $8.24 (-0.60%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Karyopharm team, including Richard Paulson, CEO; Mike Mason, CFO; and Jatin Shah, the CMO. Thanks for joining us today for our London conference.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Absolutely. Great to be here, Maury.

Questions & Answers

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

And we're going to do a fireside chat format. So maybe to start off, for those who may be new to the story, can you provide a 1-minute intro to Karyopharm?

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Sure. I mean when you look at Karyopharm, we're still a young company. We are an innovation and science-based commercial-stage pharmaceutical company now that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot